DATA SHEET 1. PRODUCT NAME (strength …
171211 Xarelto DS Page 3 of 35 After the initial 3 weeks treatment Xarelto should be continued at 20 mg once daily. Therapy should be …
Download DATA SHEET 1. PRODUCT NAME (strength …
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
What is the most important information I should …
www.janssenlabels.comMEDICATION GUIDE XARELTO® (zah-REL-toe) (rivaroxaban) tablets What is the most important information I should know about XARELTO? • For people taking XARELTO for atrial fibrillation: People with atrial fibrillation (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu4 The crushed Xarelto tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water
Conversion Table for Oral Anticoagulants in A-Fib …
www.gwinnettmd.orgConversion Table for Oral Anticoagulants in A-Fib (updated 5/6/2013) SWITCH…. Xarelto (rivaroxaban) Pradaxa (dabigatran) Eliquis (apixaban) From Warfarin D/C warfarin and start Xarelto once INR < 3 D/C warfarin and start Pradaxa once INR < 2
BIJLAGE A: Model van aanvraagformulier: I - …
www.huisarts.beVersie geldig vanaf 01.05.2016 BIJLAGE A: Model van aanvraagformulier: Aanvraagformulier voor terugbetaling van de specialiteit XARELTO (§ 7450000 van hoofdstuk IV van het KB van 21 december 2001)
ZĀĻU APRAKSTS 15 mg 20 mg - lfb.lv
www.lfb.lvXarelto 15 mg un 20 mg apvalkotās tabletes. Zāļu apraksts. 4 Parenterālo antikoagulantu nomainīšana ar Xarelto Pacientiem, kuri lieto parenterālu antikoagulantu, Xarelto lietošana jāuzsāk 0 līdz 2 stundas
Qué es Xarelto - CETE
www.tromboembolismo.com1 ¿Qué es Xarelto® y para qué se utiliza? Xarelto® 10 mg (rivaroxaban) en comprimidos recubiertos con película Xarelto® pertenece a un grupo de fármacos que se conocen como anticoagulantes orales que bloquean el factor de la coagulación Xa (factor X activo) y, por ende, reducen la tendencia de la sangre a formar coágulos.
Package leaflet: Information for the user - Medicines
www.medicines.org.ukPage 2 of 8 v019_0 Xarelto belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.